Agios Pharmaceuticals Inc

AGIO

Equity

ISIN US00847X1046 / Valor 21630028

NASDAQ (2024-11-20)

USD 54.62+0.39%

Agios Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Agios Pharmaceuticals Inc is a biopharmaceutical company that specializes in the discovery and development of novel therapies for rare diseases, with a particular emphasis on hemolytic anemias. Leveraging its expertise in cellular metabolism, Agios has made significant strides in the field, marked by the FDA approval of its first rare disease therapy for adults with pyruvate kinase (PK) deficiency. The company's pipeline includes mitapivat, its lead product candidate currently undergoing late-stage clinical trials for thalassemia and sickle cell disease. Additionally, Agios is working on AG-946, a new PK activator aimed at treating hemolytic anemias among other conditions. Beyond these leading programs, Agios is actively engaged in preclinical development, working on advancing a range of investigational therapies that promise to further its mission of addressing unmet medical needs in rare disease communities.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

154%1Y

42.9%3Y

47.6%5Y

Performance

51.6%1Y

54.6%3Y

53.9%5Y

Volatility